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Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected almost every country in the world since De-
cember 2019. Despite the efforts of the human race to combat the virus, we are still looking for an evidence-based permanent 
cure for the disease. Ivermectin has recently emerged as one of the therapies having a beneficial effect on COVID-19. Ivermectin, 
owing to its properties, continues to be a possible treatment against the COVID-19 disease. Already being a mainstream drug 
with minimal adverse effects, it garners valid consideration. It’s use in hospitalized patients, randomized controlled trials, and 
observational studies has also supported its implementation. In this article, we have reviewed recent studies and explored the 
effectiveness of ivermectin in hospitalized COVID-19 patients. 
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Introduction
SARS-CoV-2 is a single-stranded RNA virus 
from the Coronaviridae family. There are 7 known 
species of the coronavirus that have the ability to 
infect humans. Its predecessor, SARS-CoV-1, can 
also cause severe respiratory disease. It comes as 
no surprise that, with little risk involved, there 
was not enough research done on SARS viruses 
which meant that we had to face a pandemic 
without much information about the causative 
agent. As of 21 February 2021, over 110 million 
people have been infected by the virus and about 
2.4 million have lost their lives [1]. COVID-19 has 
also had a significant impact on the economic 
state of the whole world accounting for huge loss-
es and unemployment. With so much going on, 
there has been immense pressure to find a suitable 
treatment for the disease. As such, interferon, 
hydroxychloroquine, chloroquine, conventional 
anti-virals, monoclonal antibodies, convalescent 
plasma therapy, and tocilizumab have been sug-
gested as possible therapeutic options. However, 
studies have shown non-conclusive or insignifi-
cant evidence when it comes to patient mortality 
and other outcomes like disease progression, time 
to clinical stability, need of invasive ventilation, 
and duration of hospital stay [2–7]. This leaves 
the door open for debates on the efficacy of these 
drugs and whether clinicians should consider us-
ing them. So far, only corticosteroids have shown 
consistent encouraging signs towards a favorable 
prognosis of the disease [8]. 
Ivermectin has recently surfaced as one of 
the medicines showing promise in the therapy of 
COVID-19. They belong to the class of anti-para-
sitics called avermectins. First discovered in the 
1970s, it has been recognized as a ‘wonder drug’ 
and its discovery earned a Nobel Prize for Physiol-
ogy or Medicine in 2015 [9]. Since then, the drug 
has been used against a wide range of parasitic 
diseases like onchocerciasis, strongyloidiasis, 
and ascariasis both in humans and animals. It is 
currently FDA-approved and continues to be sold 
across the globe. It may be used orally or applied 
topically depending on the infection site.
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Mechanism of action 
Ivermectin primarily amplifies the activity of 
GABA receptors or glutamate-gated chloride ion 
channels which leads to the inhibition of paral-
ysis of somatic muscles via inhibition of myosin 
chain phosphorylation [10]. It is the blood-brain 
barrier (BBB) in vertebrates that protects them 
from the harmful effects of the drug in the central 
nervous system (CNS). Invertebrates, in contrast, 
are vulnerable to the actions of the drug due to 
a lack of the BBB. The fascinating part about 
ivermectin is its ability to affect a broad-range of 
diseases — it has shown anti-microbial, anti-can-
cer [11], and anti-viral properties.
The anti-viral properties of ivermectin main-
ly stem from its capacity to hinder the transport of 
viral proteins into the host nucleus via inhibition 
of the importin (IMP) a/b receptor. This allows 
it to inhibit the replication processes in various 
RNA and DNA viruses (e.g. Influenza, Zika Virus, 
Dengue Virus, Porcine circovirus, and others) [12, 
13]. Indeed, in-vitro models support the theory 
that in SARS-CoV-2 a similar inhibitory effect 
leading to decreased replication will be seen 
[14]. Computer simulations claim that ivermectin 
might also bind to the S protein of the virus or to 
ACE-2 in humans thereby warding of host cells 
from COVID-19 [15]. Another possible means by 
which ivermectin mediates its anti-viral proper-
ties is via allosteric modulation of the P2X4 recep-
tor, which leads to the secretion of CCL-5 using 
ATP [16]. Some studies suggest that ivermectin 
might have immunosuppressive effects [17, 18]. 
This is particularly important since it may point 
to the possibility of ivermectin playing a com-
plementary role of mitigating the inflammatory 
response during severe acute respiratory syn-
drome. As a matter of fact, evidence supports the 
use of ivermectin as an anti-Inflammatory drug 
in the treatment of existing diseases like Rosacea 
[19]. The results were quite optimistic in animal 
models as well [20]. 
The aim of this review is to provide a syn-
opsis of the literature on the interaction between 
COVID-19 and ivermectin while trying to gauge 
the potential use of the drug against this devas-
tating disease.
Materials and methods
We searched peer-reviewed databases such 
as PubMed and reviewed pre-print articles. We 
chose randomized controlled trials (RCTs) and 
observational studies in the English language 
that evaluated the effectiveness of ivermectin on 
COVID-19 patients compared against standard 
treatment protocol, placebo, or other prospective 
medications in their study. Our review includes 
studies that were done on PCR-confirmed hospi-
talized COVID-19 patients. Factors such as dos-
age, timing, frequency, control group exposure, 
or publication status were not considered as 
appropriate filters.
The outcomes taken into consideration in-
clude:
1. Patient Mortality
2. C-Reactive Protein level
3. Time to discharge from the hospital
4. Viral load/clearance
Data extraction was carried out by the 2 re-
viewers independently. Articles were excluded 
if they were commentaries or opinion piec-
es. Studies examining the prophylactic effects of 
ivermectin in SARS-CoV-2 were also excluded. 
Duplicate articles, if any, were removed with the 
help of Mendeley software. Citations and data 
were included when considered appropriate. Any 
disagreement between the two reviewers was 
settled by a third, independent reviewer.
Results 
After going through the databases, 14 stud-
ies were included in this review. Out of these, 
8 were randomized controlled trials and 6 were 
observational studies. Of these 14 studies, 
6 studies were peer-reviewed while 8 were pre-
prints. A cumulative total of 7,744 laboratory-con-
firmed COVID-19 patients were involved — with 
1,330 patients being a part of the ivermectin 
exposed group. 
Patient mortality was reported in 8 studies 
which included a total of 6,770 patients. Out of 
these 6,770 patients, mortality was seen in 17.57% 
(n = 1,190) of patients, of which 82 were from the 
ivermectin exposed group. Only two studies did 
not classify patients according to severity of dis-
ease (Babalola et al. [21] and Soto-Beccerra et al. 
[22]). The rest of the trials included mild, moder-
ate, and severely ill COVID-19 patients. A majori-
ty of subjects had comorbidities such as diabetes 
mellitus, hypertension, or various pulmonary 
diseases.
Table 1 describes the details of these studies 
in terms of design, dosage, size, and outcomes.
Administration and dosage of ivermectin 
varied across all studies. The lowest dosage used 
was 0.2 mg/kg, whereas the highest was 0.4 mg/kg. 
The most frequent dosage used, however, was 
0.2 mg/kg. In some cases, absolute values such as 
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6, 12, or 18 mg were used. Differences in one day 
and multi-day dosing were also noted. Just over 
a third of trials exposed the clinical group to an-
other medicine (excluding those in the standard 
of care) such as doxycycline, azithromycin, etc. 
Mortality was noted across eight different reports, 
and in almost all of them death occurrence was 
more prominent in the control arm [23–29]. The 





Control All-cause  
mortality
Other notable  
outcomes 
Elgazzar et al. [23] 
RCT
n = 400 0.4 mg/kg IVM + ST
Once daily for 4 days
HCQ + ST 1% vs 12% Reduced CRP levels 
(90% and 56% vs 84% 
and 14%) 
and hospital stay
Niaee et al. [24] 
RCT
n = 180 0.2–0.4 mg/kg IVM
Once daily or on 3 interval days
ST or 
ST + Placebo
3.3% vs 18.3% Reduced CRP levels, 
DLO, hospital stay




0.2 mg/kg IVM (once for 2–3 days) 
+ DC (twice for 5 days) + ST
ST 0% vs 27.3% 
in severely ill HP
Lower rate of progres-
sion (9% vs 31.8%) 
and hospital stay 
(avg. 7 days)
Kirti et al. [26] 
RCT
n=112 12 mg IVM (days 1 and 2) 
+ ST (days 3–6)
ST + Placebo 
6 days
0% vs 7% Did not seem to affect 
negative RT-PCR 
(23.6% vs 31.6%)
*Spoorthi et al. 
[31] 
RCT
n=100 0.2 mg/kg IVM once and/or
DC
Placebo N/A Shorter clinical recovery 
(3.7 vs 4.7 days) and 
stay (6.7 vs 7.9 days)
Ahmed et al. [30] 
RCT
n = 72 12 mg IVM + ST
Once daily for 1 or 5 day(s)
Placebo + ST N/A Faster viral clearance 
(11.5 and 9.7 
vs 12.7 days)
Babalola et al. [21] 
RCT
n = 62 6 mg or 12mg IVM + ST
Twice a week for 2 weeks
LPV/r + ST
Daily
N/A Faster viral clearance 
(4.7 and 6 vs 9 days)
Chachar et al. [32] 
RCT
n = 50 12 mg IVM + ST
3 doses in 2 days
ST N/A Difference in clinical 






n = 5683 IVM
Within 48 hours
ST 51.4% vs 42.6% —
*Rahman et al. [34] 
OBS
n = 400 18 mg IVM once + 100 mg DC 
twice daily for 5 days
HCQ + AZIT N/A Faster and better viral 
clearance (16.5% on day 
6 vs 18.5% on day 12)
*Rajter et al. [27] 
OBS






(38.8% vs 80.7% 
in severe patients)
No difference found in 
the length of stay
*Khan et al. [28] 
OBS
n = 248 12 mg IVM
Once
ST 0.9% vs 6.8% Shorter recovery time 
(9 days vs 15 days) 
and faster viral clearance 
(4 days vs 15 days)
*Gorial et al. [29]
OBS
n = 87 0.2 mg/kg IVM + HCQ + AZIT
Once
HCQ + AZT 0% vs 2.8% Shorter duration of stay 
(7.6 days vs 13.2 days) 
and faster viral clearance 
(7 days vs 12 days)
*Camprubi 
et al. [33] 
OBS
n = 26 0.2 mg/kg IVM + IS
Once on the onset of symptoms
IS N/A Small differences in 
discharges, need for ICU
*Studies with one dose of ivermectin.
AZIT — azithromycin; CRP — C-reactive protein; DC — doxycycline; DLO — duration of low O2 saturation; HCQ — hydroxychloroquine; HP — hospitalized patients; 
IS —immunosuppressants; IVM — ivermectin; LPV/r — lopinavir/ritonavir; N/A — not applicable; OBS — observational study; RCT — randomized controlled trial; 
ST — standard therapy
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only study whose findings were not consistent 
with the rest is the retrospective cohort in Peru 
by Soto-Beccerra et al. [22] which found a higher 
mortality rate in the interventional group. 
Viral clearance was recorded in 5 studies, 
all of which were able to show a reduced time 
required for viral clearance or viral load after a set 
time in the study group [21, 23, 28–30]. Perhaps 
the most pronounced effects were seen in the 
retrospective study by Khan et al. [28] in which 
the median time required for viral clearance de-
creased from 15 days to just 4 days. 
Eight trials measured the duration of hospi-
talization as an outcome. Six out of these revealed 
a shorter stay in hospitals in the ivermectin arm 
compared to the control group [23–25, 28, 29, 31]. 
In two studies, the results did not reach statistical 
significance [27, 32]. 
Out of the studies, two did not show a signif-
icant decrease in C-reactive protein (CRP) levels 
compared to the control group [29, 33], whereas 
three highlighted a statistically significant de-
crease [23, 24, 30]. In a randomized multi-center 
trial conducted by Niaee et al. [24] with p < 0.001, 
reduced CRP levels across all arms were observed. 
Out of all 5, Elgazzar et al. [23] and Niaee et al. 
[24] were the only two studies with sample sizes 
of over 100 subjects.
Patterns may also suggest the existence of 
a dose-response relationship. In one of two stud-
ies, Ahmed et al. illustrated that taking ivermectin 
for 5 days instead of 1 day increased the rate of 
viral clearance [30]. Similarly, Babalola et al. [21] 
found that the arm exposed to 12mg ivermectin 
instead of 6mg had faster clearance by over 1 day. 
However, in one case, where 3 dosing strategies 
were utilized against a control of standard therapy 
and placebo, there were similar mortality rates 
and length of hospital stays across interventional 
arms [24]. 
We also noticed one-dose trials, such as the 
one conducted by Gorial et al. [29], which saw all 
members of the study group cured against 97.2% 
of the control group. Meanwhile, the dichotomy 
in mortality rates was more pronounced in most 
multi-day dose trials (as summarized in Table 1), 
supporting the above hypothesis. Statistically, 
insignificant findings in length of hospitalization 
[27, 33] were also noted in one-time exposure 
studies, whereas only one multi-exposure study 
yielded similarly insignificant results [32]. How-
ever, a few one-dose studies did show major 
changes in at least one of the 3 categories [27–29, 
31, 34], thereby resisting the theory of there being 
a relationship.
Discussion
This review suggests that ivermectin reduc-
es mortality, CRP levels, and lengths of stay in 
the hospital while enhancing viral clearance in 
SARS-CoV-2 hospitalized patients in different 
populations around the world.
In the study carried out by Soto-Beccerra et 
al. [22], which pushes back against the notion of 
ivermectin decreasing mortality in COVID-19 pa-
tients, it should be noted that the same report 
found increased weighted hazard or unweighted 
hazard ratios in all interventional groups (others 
included azithromycin, hydroxychloroquine, or 
a combination of all 3 drugs). The data could be 
limited since zero deaths occurred on the second 
day in the control arm whereas mortality was 
reported in all other groups (deaths in the first 
24 hours were not included for both arms).
These findings are also supported by a sys-
tematic review and meta-analysis performed by 
Padhy et al. [35]. However, it should be noticed 
that they used ivermectin as an adjuvant, only 
chose 4 observational studies, and included out-
patient data. The studies chosen in this review 
are specific to hospitalized COVID-19 patients, 
larger in quantity, and include RCTs. A recent case 
series also supported these findings as 34 subjects 
treated with ivermectin all survived and mortality 
was observed in the other group(s) [36]. 
This is particularly encouraging keeping in 
view the current situation of the pandemic. The 
anti-viral activity of ivermectin seems to make it 
a very viable option for the treatment of such pa-
tients. The safety of this drug is well documented 
[37, 38]. A study that compiled data from other 
studies, including 50,000 subjects in Cameroon, 
found that only 20 faced serious complications 
[39]. Being relatively affordable and readily avail-
able makes it economically/logistically feasible.
However, we urge medical professionals 
to exercise prudence until more high-quality 
evidence is available. The COVID-19 Treatment 
Guidelines Panel at NIH stated on January 14, 
2021 that there is ‘insufficient data to recommend 
either for or against the use of ivermectin for the 
treatment of COVID-19’ due to the fact that ‘signif-
icant methodological limitations and incomplete 
information’ were visible across trials [40]. In 
addition, Merck & Co. (known as MSD outside 
USA and Canada), which originally marketed the 
drug, identified a lack of evidence on February 
4, 2021 with regards to the use of ivermectin in 
COVID-19 [41]. In a recent randomized clinical 
trial in patients with mild COVID-19 treated 
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with ivermectin, Lopez-Medina et al. [42] found 
no significant difference in time to resolution of 
symptoms in comparison with placebo. We too 
believe it is early to include ivermectin in exist-
ing protocols for similar reasons. There are other 
issues that may make ivermectin unsuitable. It is 
poor as far as water solubility is concerned, which 
is why it is not absorbed well via the oral route 
[43]. Nevertheless, it should be mentioned that 
liposomal and inhalational therapy might help 
tackle this issue. Although ivermectin is not able 
to cross the BBB, in patients with hyper-inflam-
mation, a docile BBB may permit passage into the 
CNS. As a matter of fact, we ask that quantitative 
analyses and better designed high-powered RCTs 
be run on the efficacy of the drug.
In the case of the dose-response relationship 
mentioned above, there is insufficient data to con-
clude anything. The only thing we consistently 
saw across studies was a decrease in viral load 
at higher doses when directly compared to lower 
doses [21, 23]. Although some one-dose studies 
did show smaller changes when compared to 
their multi-dosage counterparts, others found 
significant results in a few outcomes. It should be 
noted that exclusive administration of ivermectin 
across most of the aforementioned studies was 
scarce. It is possible that the significant reduction 
in viral clearance by the drug does not necessarily 
translate into early discharge from the hospital 
or a decrease in all-cause mortality. However, we 
cannot merely surmise that. We encourage other 
researchers to investigate this question while ex-
ploring the drug and its potential as a therapeutic 
option for said population.
Limitations
Due to the current COVID-19 pandemic, the 
reviewers agreed to include pre-print data in the 
article, which is not peer-reviewed. Standard 
treatment regimens, dosage, duration, inclu-
sion/exclusion criteria, and definition of severity 
of disease differed across all studies. Furthermore, 
in some trials, ivermectin was used in conjunc-
tion with either standard treatment or other drugs 
(azithromycin, doxycycline, etc.). Publication 
bias might exist in some studies.
Conclusion
Ivermectin, owing to its properties, continues 
to be a potential therapeutic option against the 
COVID-19 disease that we are facing. Already 
being a mainstream drug with minimal adverse 
effects, it garners valid consideration and atten-
tion in these times. In hospitalized patients, RCTs 
and observational studies have supported its use. 
Still, there needs to be more high-quality proof 
and quantitative analysis in order to legitimize 
its use as part of general protocol. As for now, 
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